Novo Nordisk cut ties with Hims & Hers, accusing the telehealth firm of promoting Wegovy copycat versions of the weight-loss ...

Novo Nordisk (NVO) has partnered with WeightWatchers (OTC:WGHTQ) to sell its obesity drug Wegovy days after exiting a similar ...

Novo Nordisk says the decision was made based on “Hims & Hers deceptive promotion and selling of illegitimate, knockoff versions of Wegovy that put patient safety at risk.” ...

Novo Nordisk plans to expand access to Wegovy through a collaboration with WeightWatchers, days after ending a partnership with telehealth firm Hims & Hers to sell the weight-loss drug.

Earlier this week, the pharma giant publicly accused Hims & Hers of “deceptive” marketing that is putting patient safety at risk.

She began using Wegovy, the version of Ozempic approved for weight loss, after struggling with obesity. She reveals which foods to avoid on a GLP-1 and how to prevent muscle loss.

GLP-1 drugs bought online or at compound pharmacies could cause harm, according to Tennessee Attorney General Jonathan ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

Novo Nordisk shares have come under pressure amid weight-loss drug competition, while UK health officials have launched a ...